Table 2.
Clinical description of the study population. Clinical aspects of hereditary breast and ovarian cancer (HBOC) participants.
| Clinical Data | >% | Clinical Data | % |
|---|---|---|---|
| Diagnostic age (years) | Mean 37.28 ± 3.30 | Receptor status (ER, PR, HER2/neu) | |
| BMC (kg/m2) | Mean 27.76 ± 5.59 | ER+ PR+ HER2+ | 10% |
| Disease free-survival | ER+ PR+ | 40% | |
| >36 months | 29% | ER+ HER2+ | 2% |
| <36 months No data | 21% 50% | HER2+ | 6% |
| Menarche | 11.77 ± 2.48 | ER+ | 4% |
| Menopause | Triple negative | 34% | |
| Yes | 38% | Therapy | |
| No | 62% | Chemotherapy | |
| Oral-contraceptive use | AC(4)-Taxol(12) | 28% | |
| Yes (>5 years) | 74% | Anthracyclines | 18% |
| No | 20% | Taxanes | 10% |
| Inclusion criteria | Capecitabine | 2% | |
| Family history | 41% | Not especified | 10% |
| Diagnostic >40 years | 59% | No chemotherapy | 32% |
| Births | Radiotherapy | ||
| 0 | 20% | Adjuvant | 76% |
| 1,2 | 54% | Palliative | 2% |
| 3–5 | 20% | Adjuvant/Palliative | 2% |
| >5 | 3% | No radiotherapy | 16% |
| Screening method | Hormone therapy | ||
| Autoexploration | 88% | Yes (Tamoxifen) | 54% |
| Clinical finding | 2% | No hormone therapy | 42% |
| Mastography | 4% | TNM Score | |
| Smoke | I A | 4% | |
| Yes | 78% | I B | 10% |
| No | 22% | II A | 16% |
| Histology | II B | 20% | |
| Infiltrating ductal | 74% | III A | 34% |
| Medullar carcinoma | 4% | III B | 4% |
| Lobullar | 2% | III C | 4% |
| Ductal/Lobullar | 2% | IV | 6% |
| Grade of cell differentiation | Metastasis | ||
| G1 | 6% | Bone | 10% |
| G2 | 28% | Visceral | 2% |
| G3 | 36% | Bone, visceral | 2% |
| Gx | 28% | Bone, visceral, lymph node | 2% |